Collectively, our findings provide unambiguous evidence for a non-canonical NAD+-dependent adenosinergic pathway in the lungs, implicating CD38 as a major contributor to this process with potential therapeutic value in chronic obstructive pulmonary diseases. Here, CD38 is linked to chronic obstructive pulmonary disease.